In the size class “small”, BEV only have a lower TCO for an expected lifetime that exceeds most estimates of the planning horizon people use when purchasing cars. In the size class “medium”, BEVs have a lower TCO than conventional cars if their expected lifetime mileage is high enough. “Big” electric cars have higher TCO than their conventional counterparts for any reasonable assumption regarding their use profiles.
News & events
This paper describes the methodology to make the existing interregional supply and use table (ISUT) of 2010 compatible to ESA2010/SNA2008 rules and shows the results at a macro level. The ISUT describes, for each product and industry, all intra- and interregional flows caused by the intermediate use, final consumption expenditures, investments and exports of the three Belgian regions Brussels, Flanders and Wallonia.
The cost of traffic congestion in Belgium 06/09/2019
This paper seeks to quantify the cost of the most important inefficiencies in Belgian transport taxation. To this end we calculate the welfare gain of an ideal, optimal tax/subsidy system across the transport market as a whole (i.e. considering private road traffic in conjunction with public transport). We found the total welfare gain to be 2.3 billion euros, of which 1.3 billion are due to time gains of remaining road users. Our measure lies significantly above those found in the literature, since we consider the distortion cause by a wide range of subsidies.
This Working Paper identifies the characteristics that explain severe material deprivation in Belgium, while making a distinction between people aged below 65 and those aged 65 or above. Severe material deprivation has decreased for both groups. Young people are more impacted than the elderly. Although there is a clear link between income and deprivation, the overlap between individuals identified as at risk of poverty and those as severely deprived is far from perfect. The correlation between income poverty and deprivation is weaker for the old group than for the young.
This Working Paper analyses the competitive position of the pharmaceutical industry over the 2000-2017 period. The evolution of price/cost competitiveness and non-cost competitiveness is studied based on a comparison with our neighbouring countries France, the Netherlands and Germany, and with Denmark, Ireland, Slovenia and Switzerland. The study also analyses a series of global factors and factors specific to the pharmaceutical industry that may influence competitiveness.